- Home
- TBLD vs PHAT Comparison
TBLD vs PHAT Comparison
Compare TBLD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- PHAT
- Stock Information
- Founded
- TBLD 2021
- PHAT 2018
- Country
- TBLD United States
- PHAT United States
- Employees
- TBLD N/A
- PHAT N/A
- Industry
- TBLD Investment Managers
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- PHAT Health Care
- Exchange
- TBLD Nasdaq
- PHAT Nasdaq
- Market Cap
- TBLD 633.0M
- PHAT 640.9M
- IPO Year
- TBLD N/A
- PHAT 2019
- Fundamental
- Price
- TBLD $19.91
- PHAT $10.24
- Analyst Decision
- TBLD
- PHAT Strong Buy
- Analyst Count
- TBLD 0
- PHAT 5
- Target Price
- TBLD N/A
- PHAT $16.40
- AVG Volume (30 Days)
- TBLD 97.5K
- PHAT 1.1M
- Earning Date
- TBLD 01-01-0001
- PHAT 08-07-2025
- Dividend Yield
- TBLD 6.25%
- PHAT N/A
- EPS Growth
- TBLD N/A
- PHAT N/A
- EPS
- TBLD N/A
- PHAT N/A
- Revenue
- TBLD N/A
- PHAT $114,039,000.00
- Revenue This Year
- TBLD N/A
- PHAT $194.40
- Revenue Next Year
- TBLD N/A
- PHAT $103.23
- P/E Ratio
- TBLD N/A
- PHAT N/A
- Revenue Growth
- TBLD N/A
- PHAT 1049.82
- 52 Week Low
- TBLD $15.80
- PHAT $2.21
- 52 Week High
- TBLD $20.55
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- TBLD 56.02
- PHAT 63.28
- Support Level
- TBLD $19.63
- PHAT $8.03
- Resistance Level
- TBLD $20.39
- PHAT $11.19
- Average True Range (ATR)
- TBLD 0.37
- PHAT 0.63
- MACD
- TBLD 0.01
- PHAT 0.16
- Stochastic Oscillator
- TBLD 64.11
- PHAT 69.98
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.